AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,928,847 | -0.4% | 828,961 | -8.0% | 0.01% | 0.0% |
| Q2 2023 | $42,077,262 | -5.2% | 901,205 | -22.3% | 0.01% | -11.1% |
| Q1 2023 | $44,402,336 | -7.5% | 1,160,542 | +32.5% | 0.01% | -10.0% |
| Q4 2022 | $48,010,225 | +77.0% | 876,099 | +10.0% | 0.01% | +66.7% |
| Q3 2022 | $27,120,000 | +308.6% | 796,499 | +13.4% | 0.01% | +500.0% |
| Q2 2022 | $6,638,000 | -79.0% | 702,480 | -68.5% | 0.00% | -80.0% |
| Q1 2022 | $31,679,000 | -20.2% | 2,232,523 | +19.0% | 0.01% | -16.7% |
| Q4 2021 | $39,694,000 | -6.9% | 1,876,811 | -1.6% | 0.01% | -14.3% |
| Q3 2021 | $42,628,000 | +4.2% | 1,907,328 | +15.6% | 0.01% | 0.0% |
| Q2 2021 | $40,929,000 | -8.6% | 1,649,690 | +6.9% | 0.01% | -12.5% |
| Q1 2021 | $44,773,000 | +3.9% | 1,543,330 | -7.6% | 0.01% | 0.0% |
| Q4 2020 | $43,099,000 | -21.9% | 1,670,510 | -6.8% | 0.01% | -27.3% |
| Q3 2020 | $55,186,000 | +26952.0% | 1,792,313 | +21762.8% | 0.01% | – |
| Q2 2020 | $204,000 | -96.3% | 8,198 | -96.7% | 0.00% | -100.0% |
| Q4 2019 | $5,466,000 | -10.4% | 246,301 | -8.1% | 0.00% | 0.0% |
| Q3 2019 | $6,098,000 | -4.1% | 268,067 | -19.3% | 0.00% | 0.0% |
| Q2 2019 | $6,361,000 | – | 332,160 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |